NEW HAVEN, Conn. and SHANGHAI, Sept. 28, 2020 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN, “Biohaven”) announced today that BioShin Limited (“BioShin”) its…
BioShin, Biohaven’s Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Region
– Initiating NURTEC ODT Phase 3 study for acute migraine in China and Korea, and China registrational study of troriluzole in Spinocerebellar Ataxia in 4Q20…